| Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy A Mankodi, MP Takahashi, H Jiang, CL Beck, WJ Bowers, RT Moxley, ... Molecular cell 10 (1), 35-44, 2002 | 773 | 2002 |
| Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind … JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... The Lancet Neurology 16 (12), 976-986, 2017 | 586 | 2017 |
| Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy K Charizanis, KY Lee, R Batra, M Goodwin, C Zhang, Y Yuan, L Shiue, ... Neuron 75 (3), 437-450, 2012 | 366 | 2012 |
| Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy C Fugier, AF Klein, C Hammer, S Vassilopoulos, Y Ivarsson, A Toussaint, ... Nature medicine 17 (6), 720-725, 2011 | 347 | 2011 |
| Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy F Rau, F Freyermuth, C Fugier, JP Villemin, MC Fischer, B Jost, ... Nature structural & molecular biology 18 (7), 840-845, 2011 | 319 | 2011 |
| Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in myotonic dystrophy type 1 T Kimura, M Nakamori, JD Lueck, P Pouliquin, F Aoike, H Fujimura, ... Human molecular genetics 14 (15), 2189-2200, 2005 | 310 | 2005 |
| Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial JF Howard, V Bril, T Vu, C Karam, S Peric, T Margania, H Murai, ... The Lancet Neurology 20 (7), 526-536, 2021 | 277 | 2021 |
| Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis S Muppidi, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... Muscle & nerve 60 (1), 14-24, 2019 | 186 | 2019 |
| Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy F Freyermuth, F Rau, Y Kokunai, T Linke, C Sellier, M Nakamori, Y Kino, ... Nature communications 7 (1), 11067, 2016 | 175 | 2016 |
| A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo M Nakamori, GB Panigrahi, S Lanni, T Gall-Duncan, H Hayakawa, ... Nature genetics 52 (2), 146-159, 2020 | 120 | 2020 |
| Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1 S Hino, S Kondo, H Sekiya, A Saito, S Kanemoto, T Murakami, K Chihara, ... Human molecular genetics 16 (23), 2834-2843, 2007 | 120 | 2007 |
| Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain K Suenaga, KY Lee, M Nakamori, Y Tatsumi, MP Takahashi, H Fujimura, ... PloS one 7 (3), e33218, 2012 | 99 | 2012 |
| Intracellular calcium increase induced by GABA in visual cortex of fetal and neonatal rats and its disappearance with development MH Lin, MP Takahashi, Y Takahashi, T Tsumoto Neuroscience research 20 (1), 85-94, 1994 | 88 | 1994 |
| A Kir3. 4 mutation causes Andersen–Tawil syndrome by an inhibitory effect on Kir2. 1 Y Kokunai, T Nakata, M Furuta, S Sakata, H Kimura, T Aiba, M Yoshinaga, ... Neurology 82 (12), 1058-1064, 2014 | 79 | 2014 |
| Enhanced slow inactivation by V445M: a sodium channel mutation associated with myotonia MP Takahashi, SC Cannon Biophysical journal 76 (2), 861-868, 1999 | 77 | 1999 |
| Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy M Nakamori, K Taylor, H Mochizuki, K Sobczak, MP Takahashi Annals of clinical and translational neurology 3 (1), 42-54, 2016 | 75 | 2016 |
| Endoplasmic reticulum stress in myotonic dystrophy type 1 muscle K Ikezoe, M Nakamori, H Furuya, H Arahata, S Kanemoto, T Kimura, ... Acta neuropathologica 114, 527-535, 2007 | 68 | 2007 |
| rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences C Sellier, E Cerro-Herreros, M Blatter, F Freyermuth, A Gaucherot, ... Nature communications 9 (1), 2009, 2018 | 65 | 2018 |
| Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study JF Howard, S Bresch, A Genge, C Hewamadduma, J Hinton, Y Hussain, ... The Lancet Neurology 22 (5), 395-406, 2023 | 64 | 2023 |
| Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study V Bril, A Drużdż, J Grosskreutz, AA Habib, R Mantegazza, S Sacconi, ... The Lancet Neurology 22 (5), 383-394, 2023 | 63 | 2023 |
